Clinical Trial Update: 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 study evaluating 6-Hydroxymethylacylfulvene (Irofulven) in patients with metastatic kidney cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Irofulven (irofulven)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED